CDK12抑制可减轻强直性肌营养不良患者细胞和小鼠模型中的异常
1型强直性肌营养不良(DM1)是由DMPK基因3'非翻译区CTG重复扩增转录产生的RNA疾病,目前无治疗。研究报道小分子抑制剂可清除核内焦点,在HSALR小鼠模型中减少转基因表达并改善肌强直、剪接和中央核。通过化学蛋白质组学与细胞实验鉴定CDK12为可成药靶点,其抑制降低重复扩增RNA表达。
要点
- CDK12在DM1细胞系和患者肌肉活检中升高,抑制其活性可减少重复扩增RNA表达。
- 小分子抑制剂能清除DM1细胞核内焦点,并在HSALR小鼠中改善肌强直和剪接异常。
- 部分已进入其他适应症临床试验的CDK12抑制剂可作为DM1药物开发的起点。
核心结论
- CDK12是DM1的可成药靶点,其抑制可清除核内焦点并改善小鼠模型表型。
研究设计与样本
- 研究使用小分子抑制剂在DM1患者细胞和HSALR小鼠模型中进行实验,并结合化学蛋白质组学与细胞学检测鉴定靶点。
主要发现
- 抑制剂在HSALR小鼠中减少转基因表达,改善肌强直、剪接异常和中央核。
- CDK12在DM1细胞系和患者肌肉活检中表达升高,抑制CDK12可降低重复扩增RNA表达。
临床怎么用
- 部分已进入其他适应症临床试验的CDK12抑制剂可作为DM1药物开发的起点。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Myotonic dystrophy type 1 (DM1) is an RNA-based disease with no current treatment. It is caused by a transcribed CTG repeat expansion within the 3' untranslated region of the dystrophia myotonica protein kinase (DMPK) gene. Mutant repeat expansion transcripts remain in the nuclei of patients' cells, forming distinct microscopically detectable foci that contribute substantially to the pathophysiology of the condition. Here, we report small-molecule inhibitors that remove nuclear foci and have beneficial effects in the HSALR mouse model, reducing transgene expression, leading to improvements in myotonia, splicing, and centralized nuclei. Using chemoproteomics in combination with cell-based assays, we identify cyclin-dependent kinase 12 (CDK12) as a druggable target for this condition. CDK12 is a protein elevated in DM1 cell lines and patient muscle biopsies, and our results showed that its inhibition led to reduced expression of repeat expansion RNA. Some of the inhibitors identified in this study are currently the subject of clinical trials for other indications and provide valuable starting points for a drug development program in DM1.
引用
- Ketley A, Wojciechowska M, Ghidelli-Disse S, et al. CDK12 inhibition reduces abnormalities in cells from patients with myotonic dystrophy and in a mouse model. Sci Transl Med. 2020. PMID: 32350131. doi:10.1126/scitranslmed.aaz2415
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。